Shenzhen Neptunus Interlong Bio-technique Company Limited (“Neptunus Interlong”) reported a net loss attributable to shareholders of RMB40.74 million for the year ended 31 December 2025, reversing the prior-year profit of RMB25.01 million. Including minority interests, the Group recorded a total comprehensive loss of RMB53.10 million.
\n\nRevenue fell 6.69% to RMB972.01 million, dragged by both core divisions: • Manufacturing and selling of medicines and medical devices declined 10.04% to RMB486.38 million, representing 50.04% of group turnover. • Sales and distribution of medicines, healthcare products and medical devices slipped 3.09% to RMB485.63 million, accounting for 49.96% of turnover.
\n\nGross profit contracted 12.45% to RMB289.33 million, and the gross margin narrowed to 29.78% from 31.72%, mainly due to lower contribution from high-margin products.
\n\nOperating performance was pressured by a RMB63.42 million goodwill impairment on subsidiary Neptunus Zhongxin and higher inventory and receivable write-downs, lifting other operating expenses to RMB117.89 million (2024: RMB56.06 million). Selling and distribution expenses decreased 15.97% to RMB136.43 million following a change in the sales model, while administrative expenses were broadly stable at RMB94.90 million. Finance costs dropped 18.51% to RMB4.14 million on reduced bank-loan interest.
\n\nThe Group generated negative operating profit of RMB44.42 million versus a RMB34.72 million profit a year earlier. After income tax of RMB4.54 million, basic loss per share equated to RMB2.43 cents (2024 earnings per share: RMB1.49 cents).
\n\nBalance-sheet highlights: • Net current assets stood at RMB327.82 million (2024: RMB468.60 million), reflecting lower cash and deposits. • Cash and cash equivalents declined by RMB84.07 million to RMB199.36 million. • Interest-bearing borrowings dropped to RMB71.00 million from RMB101.72 million; the year-end gearing ratio rose to 50.08% due to reduced equity. • Total equity fell to RMB704.01 million from RMB1.03 billion, chiefly because of the loss for the year and the RMB244.99 million dividend payout approved and paid in 2025.
\n\nCapital expenditure (additions to non-current assets) reached RMB17.58 million, down from RMB29.10 million a year earlier. The Group's pledged assets included RMB13.52 million in buildings and RMB2.51 million in furniture, fixtures and equipment securing bank and other borrowings.
\n\nNo final or special dividend was proposed for FY2025, compared with a combined RMB0.146 per share distribution declared for FY2024.
\n\nManagement highlighted ongoing optimisation of product mix, cost control, and market expansion efforts, with particular focus on traditional Chinese medicine, healthcare food products, and commissioned manufacturing to improve performance in the coming periods.
Comments